50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
QQQ   274.48 (+0.04%)
AAPL   151.76 (+0.66%)
MSFT   236.41 (-0.44%)
META   134.40 (-1.44%)
GOOGL   97.50 (-0.68%)
AMZN   114.41 (-0.64%)
TSLA   282.94 (+2.51%)
NVDA   124.13 (+1.51%)
NIO   17.19 (-2.44%)
BABA   77.87 (-1.32%)
AMD   67.17 (+1.31%)
T   15.73 (+0.38%)
MU   50.58 (+3.48%)
CGC   2.86 (+4.38%)
F   11.91 (-0.67%)
GE   64.47 (+0.19%)
DIS   95.85 (-2.31%)
AMC   7.45 (+9.08%)
PYPL   85.75 (+1.77%)
PFE   44.09 (+0.59%)
NFLX   224.36 (+0.13%)
NASDAQ:VIVO

Meridian Bioscience - VIVO Stock Forecast, Price & News

$31.63
-0.12 (-0.38%)
(As of 09/27/2022 04:30 PM ET)
Add
Compare
Today's Range
$31.51
$31.94
50-Day Range
$31.44
$33.10
52-Week Range
$17.20
$34.38
Volume
269,036 shs
Average Volume
552,916 shs
Market Capitalization
$1.38 billion
P/E Ratio
31.95
Dividend Yield
N/A
Price Target
$34.00

Meridian Bioscience MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
7.7% Upside
$34.00 Price Target
Short Interest
Healthy
7.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.41
Upright™ Environmental Score
News Sentiment
0.47mentions of Meridian Bioscience in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$1.87 M Sold Last Quarter
Proj. Earnings Growth
-34.09%
From $1.32 to $0.87 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

890th out of 1,071 stocks

Diagnostic Substances Industry

14th out of 17 stocks

VIVO stock logo

About Meridian Bioscience (NASDAQ:VIVO) Stock

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand. This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood. It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

Receive VIVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

VIVO Stock News Headlines

VIVO Meridian Bioscience, Inc.
SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates VIVO, SAVE, AAWW, MNRL
Meridian Bioscience Inc
Meridian Bioscience (VIVO) Meets Q3 Earnings Estimates
See More Headlines
Receive VIVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Meridian Bioscience and its competitors with MarketBeat's FREE daily newsletter.

VIVO Company Calendar

Last Earnings
11/12/2021
Today
9/27/2022
Fiscal Year End
9/30/2022
Next Earnings (Estimated)
11/11/2022

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:VIVO
CUSIP
58958410
Employees
702
Year Founded
1977

Price Target and Rating

Average Stock Price Forecast
$34.00
High Stock Price Forecast
$34.00
Low Stock Price Forecast
$34.00
Forecasted Upside/Downside
+7.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
2 Analysts

Profitability

Net Income
$71.41 million
Pretax Margin
16.75%

Debt

Sales & Book Value

Annual Sales
$317.90 million
Cash Flow
$2.02 per share
Book Value
$7.57 per share

Miscellaneous

Free Float
42,742,000
Market Cap
$1.38 billion
Optionable
Optionable
Beta
0.27

Social Links


Key Executives

  • Mr. John P. KennyMr. John P. Kenny (Age 53)
    Pres, CEO & Director
    Comp: $1.51M
  • Dr. Lourdes G. Weltzien Ph.D. (Age 57)
    Exec. VP of Life Science Bus. Unit
    Comp: $665.66k
  • Mr. Tony Serafini-Lamanna (Age 59)
    Exec. VP of Diagnostics
    Comp: $600.53k
  • Mr. Andrew S. KitzmillerMr. Andrew S. Kitzmiller (Age 42)
    Exec. VP & CFO
  • Julie Smith
    Sr. VP, Controller & Principal Accounting Officer
  • Mr. Jeff Pinkston
    Director of Corp. Fin.
  • Mr. Charles Wood
    VP of Corp. Strategy, Bus. Devel. & Investor Relations
  • Ms. Melissa J. McCarey
    VP of Global HR
  • Ms. Susan D. Rolih (Age 73)
    Consultant
  • Ms. Melissa A. Lueke (Age 59)
    Consultant













VIVO Stock - Frequently Asked Questions

Should I buy or sell Meridian Bioscience stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last twelve months. There are currently 2 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" VIVO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VIVO, but not buy additional shares or sell existing shares.
View VIVO analyst ratings
or view top-rated stocks.

What is Meridian Bioscience's stock price forecast for 2022?

2 brokers have issued 1 year price targets for Meridian Bioscience's stock. Their VIVO share price forecasts range from $34.00 to $34.00. On average, they anticipate the company's share price to reach $34.00 in the next year. This suggests a possible upside of 7.5% from the stock's current price.
View analysts price targets for VIVO
or view top-rated stocks among Wall Street analysts.

How have VIVO shares performed in 2022?

Meridian Bioscience's stock was trading at $20.40 at the beginning of the year. Since then, VIVO shares have increased by 55.0% and is now trading at $31.62.
View the best growth stocks for 2022 here
.

When is Meridian Bioscience's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our VIVO earnings forecast
.

How were Meridian Bioscience's earnings last quarter?

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its earnings results on Friday, November, 12th. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.21 by $0.03. The firm had revenue of $76.20 million for the quarter, compared to analyst estimates of $68.40 million. Meridian Bioscience had a trailing twelve-month return on equity of 17.55% and a net margin of 12.58%. During the same quarter last year, the business earned $0.19 earnings per share.

What guidance has Meridian Bioscience issued on next quarter's earnings?

Meridian Bioscience updated its third quarter 2022 earnings guidance on Thursday, July, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $66.00 million-$69.00 million, compared to the consensus revenue estimate of $69.57 million.

What is Jack Kenny's approval rating as Meridian Bioscience's CEO?

7 employees have rated Meridian Bioscience Chief Executive Officer Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among the company's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Meridian Bioscience own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

What is Meridian Bioscience's stock symbol?

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Who are Meridian Bioscience's major shareholders?

Meridian Bioscience's stock is owned by many different institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (4.64%), FMR LLC (4.46%), Royce & Associates LP (3.85%), State Street Corp (3.72%), Northern Trust Corp (1.23%) and Wells Fargo & Company MN (0.69%). Insiders that own company stock include Andrew S Kitzmiller, Anthony P Bihl III, Bryan T Baldasare, David Phillips, Felicia Williams, John Mccune Jr Rice, John Mcilwraith, John P Kenny and Lourdes Weltzien.
View institutional ownership trends
.

How do I buy shares of Meridian Bioscience?

Shares of VIVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Meridian Bioscience's stock price today?

One share of VIVO stock can currently be purchased for approximately $31.62.

How much money does Meridian Bioscience make?

Meridian Bioscience (NASDAQ:VIVO) has a market capitalization of $1.38 billion and generates $317.90 million in revenue each year. The company earns $71.41 million in net income (profit) each year or $0.99 on an earnings per share basis.

How many employees does Meridian Bioscience have?

The company employs 702 workers across the globe.

Does Meridian Bioscience have any subsidiaries?
The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.
Read More
How can I contact Meridian Bioscience?

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The official website for the company is www.meridianbioscience.com. The company can be reached via phone at (513) 271-3700, via email at mbi@meridianbioscience.com, or via fax at 513-271-3762.

This page (NASDAQ:VIVO) was last updated on 9/27/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.